Combining CAR-T with CAR-Treg All in One Dr. Alfred Kim reports on abstract 0981 (GNTI-350: A CAR-Treg Therapy Offering Durable Immune Reset with Improved Safety for B Cell–Driven Autoimmune Diseases). rheumnow.com/video/combin...

Korean study 481 pts w/ myositis (IIM) - 12.9% w/ myositis-assoc. cancer. CA risk factos= older, male, current smoking, dermatomyositis, TIF1γ; but lower risk w/ anti-synthetase synd, overlap myositis, arthritis, & ILD. SCRIM score AUROC 0.852 arthritis-research.biomedcentral.com/articles/10....

Genentech announced positive results from the phase III DBRPCT ALLEGORY trial showin safety & efficacy of obinutuzumab in ~300 SLE pts on SOC. Results have yet to be presented publicly. www.businesswire.com/news/home/20...

Systematic review 10 studies showed TNFi exposure in utero not assoc w/ incr risk of infant severe infxn (4 RCTs); same for breast milk exposure (2 RCTs). Infant vaccination outcomes unaffected by TNFi use, but rec delaying BCG vaccination if TNFi exposed journals.lww.com/ijwd/fulltex...?

Bone Density in Ankylosing Spondylitis At #ACR25, a retrospective study from China tackled this challenge using quantitative computed tomography (QCT), a more precise imaging modality that measures true volumetric bone density unaffected by cortical ossifications. rheumnow.com/news/bone-de...

IL-23 Blockade Goes Oral A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the IL-23R, is showing encouraging efficacy and safety across a range of PSO and PsD studies. rheumnow.com/news/il-23-b...

#ACR25 RA Topic Panel A focused conversation on the latest in psoriatic arthritis care — from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what’s shaping PsA practice right now. buff.ly/6jNE5a5

In 2024, 77 pts referred to Rheum for PMR were ultimately Dx w/ B19 viral infx. 96% had arthralgia & 7% had PMR-like features (5/5 w/ BL shoulder/neck. prolonged AM stiff, fever & Hi CRP/ESR - none had hip pain. 4/5 were male, w/ mean age of 55 yrs. None were RF/CCP+ www.jrheum.org/content/52/5...

There OA burden is growing in middle-aged adults, rising by 124%, from 11.8 million in 1990 to 26.4 million in 2021. 56.5% of incident & 38% of prevalent cases occur in middle-aged group (70% higher than the elderly (>60 years) population). Highest in hi-income. academic.oup.com/rheumatology...

20-40% of Autoimmune hepatitis (AIH) is assoc with other autoimmune diseases - lead by autoimmune thyroiditis, type 1 DM, ulcerative colitis, Crohn disease, & celiac (but less so for RA, PBC, SLE, Sjögren syndrome, vitiligo). AIH Dx Abs include ANA, ASMA, LKM1. www.eurekalert.org/news-release...

Sjogren’s disease: two drugs with positive trials Sjogren’s disease: two drugs with positive trials At #ACR25, not one but two drugs presented their efficacy and safety data in patients with moderate to severe disease activity as defined by ESSDAI score ≥ 5 points. rheumnow.com/news/sjogren...

RETREAT study was a 12 wk RCT of Tai Chi in 178 knee OA pts Rx w/ online OA info vs same plus free web based tai chi video program. Tai Chi group had signif improved knee pain (−2.7 v -1.2); (−12 v −6.9) & achieved a minimal pain & function (73% v 47%); and Its free! jamanetwork.com/journals/jam...

Off the Shelf: CAR-T Dr. Akhil Sood reports on abstract 0663 (iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy) presented at#ACR25. rheumnow.com/video/shelf-...

AI in Fellow Recruitment: A New Dawn in Medical Education? Drs. Mrinalini Dey and Bharat Kumar abstract 2174 (Using Natural Language Processing to Identify Character Strengths in Rheumatology Fellowship Candidate Applications: A Feasibility Study) presented at #ACR25. rheumnow.com/video/ai-fel...

Beyond the Breakthrough: Equity and Access in CAR-T Cell Therapy for RA buff.ly/hhjuPal

“It is not the strongest of the species that survive, nor the most intelligent, but the one most responsive to change." – Charles Darwin

B Cell Depletion: Check the Lymph Node Dr. Akhil Sood reports on abstract 2695 (B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents) presented at #ACR25. buff.ly/cJxSM4k

Beyond the Breakthrough: Equity and Access in CAR-T Cell Therapy for RA At #ACR25, abstract 1039 adds a critical dimension to the growing enthusiasm around cellular therapies in autoimmune disease. buff.ly/hhjuPal

IL-23 Blockade Goes Oral A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the IL-23R, is showing encouraging efficacy and safety across a range of PSO and PsD studies. rheumnow.com/news/il-23-b...

Stopping therapy in GCA rheumnow.com/news/stoppin...

Weight Loss as a Therapeutic Goal in PsA At #ACR25, 3 compelling studies spanning pharmacologic, lifestyle, and longitudinal observational data converged on a central theme: weight loss is a powerful modulator of PsA outcomes, regardless of the intervention used. rheumnow.com/news/weight-...

IgG4: Rare, but new treatments on the horizon IgG4 is a rare autoimmune disease with excessive IgG4 immunoglobulins that can affect multiple organs yielding plasma cell deposition (inflammation) and fibrosis. buff.ly/34QQkA4

Do Patients with Rheumatic Diseases 'Weather' the Storm? Dr. Janet Pope reports on abstract 0164 (Online Patient Survey on the Impact of Extreme Weather Events on Autoimmune and Rheumatic Diseases) presented at #acr25. rheumnow.com/video/do-pat...

Do Patients with Rheumatic Diseases 'Weather' the Storm? Dr. Janet Pope reports on abstract 0164 (Online Patient Survey on the Impact of Extreme Weather Events on Autoimmune and Rheumatic Diseases) presented at #ACR25. buff.ly/nWH6t8h

Upadacitinib: revisiting safety data in RA and GCA Upadacitinib remains a favored option for treating RA and ax-Spa, despite safety concerns about JAK inhibitors heightened by the ORAL Surveillance study. These concerns have led to more cautious use and stricter regulations. buff.ly/5hgvKpZ

#ACR25 Best Abstracts - Day 3 Tweeting about an ACR presentation or poster is an art mastered by the RheumNow faculty, who explore #ACR25 for top insights. Here are the best abstracts from Day 3, selected by our faculty. buff.ly/bx4EvLT

Accelerated Aging in Rheumatic Disease: From Biology to Lifestyle Intervention At #ACR25, the session “27M02: Nutrition for Rheumatic Disease” explored rheumatic disease through aging biology, emphasizing nutrition and exercise as key lifestyle interventions. buff.ly/sVSKYAJ

RheumNow Rheumatology Round-Up Stay plugged into the conversations, discoveries, and breakthroughs moving rheumatology forward. Real updates. Real context. For clinicians who never stop learning. rheumnow.com/podcast/rheu...

A Halloween ACR Guidance (10.31.25) Dr. Jack Cush recaps #ACR25 with suggestions on how to best learn ACR25 content from RheumNow and our Videos and podcasts. rheumnow.com/podcast/hall...

The Great Debate – Who Really Won? #ACR25 rheumnow.com/news/great-d...

Predicting Long-Term Proteinuria Risk in SLE Lupus nephritis affects nearly half of SLE patients, with up to a 30% mortality rate over 10 years and 10-22% progressing to end-stage kidney disease. Early detection and diagnosis are essential. rheumnow.com/news/decade-...

Belimumab Before or After Immunosuppressant Dr. Yuz Yusof reports on abstract 0803 presented at #ACR25 rheumnow.com/video/belimu...

Using AI and LLMs in Qualitative Data Dr. Bella Mehta discusses abstract 0794 (Using AI to Analyze Multilingual Qualitative Data in Lupus Pregnancy Research: A Proof of Concept with Large Language Models) presented at #ACR25 rheumnow.com/video/using-...

If We Can’t Prevent RA, Can We at Least Prevent Difficult-to-Treat RA? While understanding of D2T and drug resistance has improved, it's unclear if early intervention can prevent this. 2 studies examine if initial treatment choices affect progression to D2T. #ACR25 rheumnow.com/news/if-we-c...

The Long View of Diagnostic Delay in Axial Spondyloarthritis At #ACR25, Abstract #1407 presented a cross-sectional analysis from the Brazilian Spondyloarthritis Registry (RBE), offering a unique perspective on how diagnostic patterns have evolved over six decades. rheumnow.com/news/long-vi...

#ACR25 – Day 2 Report Here are 3 abstracts that caught my eye on Day 2 at #ACR25. Notably these have takeaway messages that should support your current practices. rheumnow.com/news/acr-202...

Cellular Biomarkers of Rheumatoid Arthritis Dr. Jeffrey Sparks reports on four abstracts at #ACR25. rheumnow.com/video/cellul...

PsA: Impact of Sex Dr. Arthur Kavanaugh highlights the importance of sex on disease characteristics and response to therapy in psoriatic arthritis, reporting from #ACR25. rheumnow.com/video/psa-im...

Nerandomilast for ILD Dr. Mike Putman reports on abstract 1662 (Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial). #ACR25 buff.ly/QS5Ag9q

#ACR25 Best Abstracts - Day 2 After a full day at the Chicago Convention center the RheumNow faculty have posted some of their favorite reports included these that they labeled as being the "best' of day 2. rheumnow.com/news/acr25-b...

Are we putting the CAR-T before the horse? CAR T-cells have revolutionized rheumatology. Patients with severe refractory autoimmune conditions now face the prospect of not just improvement but a potential cure. #ACR25 rheumnow.com/news/are-we-...

GLP-1 and SGLT-2: Treatments Too Good to Ignore? Dr. Peter Nash reviews several studies presented on GLP-1s at #ACR25. He recommends for review abstracts: 0841, 0849, 1027, 2685, 0165, 0233 and 2658. rheumnow.com/video/glp-1-...

B Cell Depletion: Check the Lymph Node Dr. Akhil Sood reports on abstract 2695 (B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents) presented at #ACR25. rheumnow.com/video/b-cell...

Psoriatic Arthritis: Which biologic agent is the best first choice? A growing arsenal of therapeutic targets in psoriatic arthritis (PsA) has enhanced the landscape of treatment in patients with this disease. rheumnow.com/news/psoriat...

New Advances in Ultrasound Diagnostics for Psoriatic Arthritis Two pivotal studies led by an international team of rheumatology experts will be presented at #ACR25, showcasing major strides in the ultrasound-based diagnosis of enthesitis in PsA. rheumnow.com/news/new-adv...

Should we be using JAKi more in female SpA patients? Recent data indicates that female patients with spondyloarthritis, including PsA and axial spondyloarthritis, may experience worse outcomes than males. rheumnow.com/news/should-...

💬 #ACR25 Topic Panels — LIVE! Nov. 4 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology: CAR-T Join Us Live on: X • Facebook • YouTube • LinkedIn • RheumNow.com Top experts. Real clinical insight. Don't miss these discussions #RheumNow #Rheumatology #ACR25 #MedEd

Nearly 40% of rheumatoid arthritis patients are 65+, yet treatment guidelines mostly derive from studies that exclude them. This raises a crucial question: do we truly understand the best way to treat older adults with rheumatic diseases? buff.ly/eGg9bHU

New research presented at #ACR25 highlights how the RISE registry is driving transformative improvements in quality, safety, and patient outcomes across rheumatic and musculoskeletal diseases. rheumnow.com/news/new-res...

Tofacitinib in AxSpA in Developing Countries Dr. Antoni Chan reports on abstracts 0582 and abstract 0554 presented at #ACR25 rheumnow.com/video/tofaci...